Select Language

PLAU

PLAU Overview

English Name	Urokinase plasminogen activator	Approved Drugs	4
Drugs in Clinical Trials	7	Target Synonym	PLAU，uPA，Plasminogen Activator， Urokinase，Urokinase-Type Plasminogen Activator，Plasminogen Activator， Urinary，BDPLT5，U-PA，ATF，QPD，URK，EC 3.4.21，EC:3.4.21.73，U-Plasminogen Activator，EC 3.4.21.73
Highest Development Stage	Approved

English Name	Urokinase plasminogen activator
Target Synonym	PLAU，uPA，Plasminogen Activator， Urokinase，Urokinase-Type Plasminogen Activator，Plasminogen Activator， Urinary，BDPLT5，U-PA，ATF，QPD，URK，EC 3.4.21，EC:3.4.21.73，U-Plasminogen Activator，EC 3.4.21.73
Approved Drugs	4
Drugs in Clinical Trials	7
Highest Development Stage	Approved

PLAU Product List

Product Category
Protein (2)
Product Status
Launched (2)
Species
Human (2)
Tag
His Tag (2)
Conjugate
Unconjugated (2)

Cat. No.	Species	Host	Product Description	Structure	Purity	Feature
PLU-H5228	Human	HEK293	Human PLAU / uPA Protein, His Tag (activated by trypsin) (active enzyme)
PLU-H5229	Human	HEK293	Human PLAU / uPA Protein, His Tag

Total: 2

PLAU Background

Urokinase - type plasminogen activator is also known as PLAU and UPA, a serine protease with an extremely limited substrate specificity, cleaving the sequence Cys – Pro – Gly - Arg560 - Val561 – Val – Gly – Gly – Cys in plasminogen to form plasmin. uPA is a potent marker of invasion and metastasis in a variety of human cancers associated with breast, stomach, colon, bladder, ovary, brain and endometrium.uPA and its receptor (uPAR) have been implicated in a broad spectrum of pathophysiological processes, including fibrinolysis, proteolysis, inflammation, atherogenesis and plaque destabilization, all of which are involved in the pathogenesis of MI (myocardial infarction).

PLAU Synonyms

Urokinase,PLAU,ATF,UPA,URK,u-PA,BDPLT5,QPD

Clinical Drug Information

English Name	Research Code	Highest Development Stage	Company	Indication	Clinical Trial
Urokinase biosimilar (Suzhou Landing Biological Pharmaceutical)		Phase 3 Clinical	Suzhou RxD Biopharmaceutical Co Ltd	ST Elevation Myocardial Infarction	Details
tPA/HisproUK (Thrombolytic Science)	TS-01	Phase 2 Clinical	Thrombolytic Science	Ischemic Stroke	Details
Upamostat Hydrogen Sulphate (Wilex)	WX-671; LH-011; RHB-107	Phase 2 Clinical	Wilex AG	Coronavirus Disease 2019 (COVID-19); Pancreatic Neoplasms; Metastatic breast cancer	Details
Recombinant human annexin 5 protein (Yabao Pharmaceuticals)	SY-005	Phase 2 Clinical	Yabao Pharmaceutical Group Co Ltd, Lawson Health Research Institute	Sepsis; Coronavirus Infections	Details
Recombinant annexin A5 (Annexin Pharmaceuticals)	ANXV; ANXV (Annexin A5); ANXV (Human Recombinant Annexin A5)	Phase 2 Clinical	Annexin Pharmaceuticals AB	Neoplasms; Cardiovascular Diseases; Anemia, Sickle Cell; Retinal Vein Occlusion	Details
MSB-03	MSB-03	Phase 1 Clinical	MatriSys Bioscience Inc	Rosacea	Details
Microlyse	TGD-001	Phase 1 Clinical	University Medical Centre Utrecht, Netherlands	Purpura, Thrombotic Thrombocytopenic; Ischemic Stroke; Thrombocytopenia	Details

Marketed Drug Information

English Name	Research Code	Highest Development Stage	Company	Earliest Brand Name	Earliest Approval Country	Earliest Indication	Earliest Approval Company	Earliest Approval Date	Indication	Clinical Trial
Urokinase biosimilar (Sedico)		Approved	Sedico	Angikinase	Egypt	Thromboembolism; Myocardial Infarction; Pulmonary Embolism	Sedico	2014-01-01	Pulmonary Embolism; Myocardial Infarction; Thromboembolism	Details
Tisokinase	AK-124	Approved	Kowa Dental Health Co Ltd, Asahi Kasei Corp	Plasvata, Hapase	Japan	Myocardial Infarction; Thrombosis	null	1991-01-01	Myocardial Infarction; Thrombosis	Details
Urokinase biosimilar (Bharat Serums & Vaccines)	U-FRAG	Approved	Bharat Serums And Vaccines Ltd						Pulmonary Embolism	Details
Nasaruplase	GE-0943	Approved	Mitsubishi Pharma Corp	Tomieze, Thrombolyse	Japan	Myocardial Infarction; Venous Thrombosis	Mitsubishi Pharma Corp	1992-01-01	Myocardial Infarction; Venous Thrombosis	Details